{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:03:57Z","timestamp":1761102237151},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13256-016-1060-y","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T01:48:24Z","timestamp":1478569704000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Gaetano","family":"Giuffrida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Di Francesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Fiumara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-3-540-74723-9_29","volume-title":"Inherited metabolic diseases: a clinical approach","author":"JA Wanders","year":"2010","unstructured":"Wanders JA, Poorthuis BJHM, Rodenburg RJT. Enzymes, metabolic pathways, flux control analysis, and the enzymology of specific groups of inherited metabolic diseases. In: Hoffmann GF, Zschocke J, Nyhan WL, editors. Inherited metabolic diseases: a clinical approach. Berlin: Springer-Verlag; 2010. p. 283\u2013303."},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","volume":"129","author":"M Jmoudiak","year":"2005","unstructured":"Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005;129:178\u201388.","journal-title":"Br J Haematol"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982;39:709\u201318.","journal-title":"J Neurochem"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1086\/302925","volume":"66","author":"V Koprivica","year":"2000","unstructured":"Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000;66:1777\u201386.","journal-title":"Am J Hum Genet"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(01)05490-3","volume":"358","author":"D Elstein","year":"2001","unstructured":"Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher\u2019s disease. Lancet. 2001;358:324\u20137.","journal-title":"Lancet"},{"key":"1060_CR6","first-page":"59","volume":"2","author":"TA Burrow","year":"2011","unstructured":"Burrow TA, Barnes S, Grabowski GA. Prevalence and management of Gaucher disease. Pediatr Health Med Ther. 2011;2:59\u201373.","journal-title":"Pediatr Health Med Ther"},{"key":"1060_CR7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/2008-132-851-GDROTL","volume":"132","author":"M Chen","year":"2008","unstructured":"Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med. 2008;132:851\u20133.","journal-title":"Arch Pathol Lab Med"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10545-010-9095-5","volume":"33","author":"P Cherin","year":"2010","unstructured":"Cherin P, Rose C, de Roux-Serratrice C, Tardy D, Dobbelaere D, Grosbois B, et al. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33:331\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","volume":"31","author":"M Biegstraaten","year":"2008","unstructured":"Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. Non-neuronopathic\u2019 Gaucher disease reconsidered: prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31:337\u201349.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1023\/B:BOLI.0000005623.60471.51","volume":"26","author":"GM Pastores","year":"2003","unstructured":"Pastores GM, Barnett NL, Bathan P, Kolodny EH. A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis. 2003;26:641\u20135.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","volume":"143","author":"O Goker-Alpan","year":"2003","unstructured":"Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr. 2003;143:273\u20136.","journal-title":"J Pediatr"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","volume":"83","author":"E Sidransky","year":"2004","unstructured":"Sidransky E. Gaucher disease: complexity in a \u201csimple\u201d disorder. Mol Genet Metab. 2004;83:6\u201315.","journal-title":"Mol Genet Metab"},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","volume":"32","author":"A Vellodi","year":"2009","unstructured":"Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis. 2009;32:660\u20134.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113:112\u20139.","journal-title":"Am J Med"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22:119\u201326.","journal-title":"J Bone Miner Res"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481\u20135.","journal-title":"Lancet"},{"key":"1060_CR17","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","volume":"269","author":"FM Platt","year":"1994","unstructured":"Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269:8362\u20135.","journal-title":"J Biol Chem"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","volume":"28","author":"R Heitner","year":"2002","unstructured":"Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002;28:127\u201333.","journal-title":"Blood Cells Mol Dis"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","volume":"27","author":"D Elstein","year":"2004","unstructured":"Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757\u201366.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1750-1172-7-102","volume":"7","author":"TM Cox","year":"2012","unstructured":"Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, et al. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012;7:102.","journal-title":"Orphanet J Rare Dis"},{"key":"1060_CR21","unstructured":"Zavesca (miglustat). Summary of product characteristics 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000435\/human_med_001171.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125 . Accessed 17 June 2016."},{"key":"1060_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"1060_CR23","first-page":"CD010324","volume":"3","author":"E Shemesh","year":"2015","unstructured":"Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015;3:CD010324.","journal-title":"Cochrane Database Syst Rev"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1006\/bcmd.1999.0231","volume":"25","author":"S Aviner","year":"1999","unstructured":"Aviner S, Levy Y, Yaniv I, Cohen IJ. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient. Blood Cells Mol Dis. 1999;25:92\u20134.","journal-title":"Blood Cells Mol Dis"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122:33\u20139.","journal-title":"Ann Intern Med"},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","volume":"90","author":"K Starzyk","year":"2007","unstructured":"Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90:157\u201363.","journal-title":"Mol Genet Metab"},{"key":"1060_CR27","first-page":"407","volume":"3","author":"D Elstein","year":"2009","unstructured":"Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics. 2009;3:407\u201317.","journal-title":"Biologics"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000339754","volume":"160","author":"D Erdogdu","year":"2013","unstructured":"Erdogdu D, Gelincik A, Canbaz B, Colakoglu B, Buyukozturk S, Tanakol R. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease. Int Arch Allerg Immunol. 2013;160:215\u20137.","journal-title":"Int Arch Allerg Immunol"},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jpeds.2009.05.033","volume":"155","author":"DG Peroni","year":"2009","unstructured":"Peroni DG, Pescollderungg L, Piacentini GL, Cassar W, Boner AL. Effective desensitization to imiglucerase in a patient with type I Gaucher disease. J Pediatr. 2009;155:940\u20131.","journal-title":"J Pediatr"},{"key":"1060_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","volume":"29","author":"JM Aerts","year":"2006","unstructured":"Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449\u201356.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR31","first-page":"703","volume":"91","author":"P Giraldo","year":"2006","unstructured":"Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, et al. Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher\u2019s disease. Haematologica. 2006;91:703\u20136.","journal-title":"Haematologica"},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","volume":"94","author":"P Giraldo","year":"2009","unstructured":"Giraldo P, Alfonso P, Atutxa K, Fernandez-Galan MA, Barez A, Franco R, et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009;94:1771\u20135.","journal-title":"Haematologica"},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","volume":"51","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013;51:116\u201324.","journal-title":"Blood Cells Mol Dis"},{"key":"1060_CR34","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110:2296\u2013301.","journal-title":"Blood"},{"key":"1060_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13256-015-0617-5","volume":"9","author":"C Serratrice","year":"2015","unstructured":"Serratrice C, Swiader L, Serratrice J. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series. J Med Case Rep. 2015;9:146.","journal-title":"J Med Case Rep"},{"key":"1060_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/00498250601094543","volume":"37","author":"A Treiber","year":"2007","unstructured":"Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37:298\u2013314.","journal-title":"Xenobiotica"},{"key":"1060_CR37","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","volume":"29","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007;29:1645\u201354.","journal-title":"Clin Ther"},{"key":"1060_CR38","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18:770\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/pds.3760","volume":"24","author":"M Brand","year":"2015","unstructured":"Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D. Results from a 9-year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca\u00ae)-treated patients. Pharmacoepidemiol Drug Saf. 2015;24:329\u201333.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1060_CR40","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","volume":"34","author":"N Belmatoug","year":"2011","unstructured":"Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34:991\u20131001.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR41","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10545-012-9523-9","volume":"35","author":"M Amiri","year":"2012","unstructured":"Amiri M, Naim HY. Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of \u03b1-glucosidases, but not \u03b2-galactosidases. J Inherit Metab Dis. 2012;35:949\u201354.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0755-4982(04)98639-3","volume":"33","author":"P D\u00e9chelotte","year":"2004","unstructured":"D\u00e9chelotte P. Type 1 Gaucher\u2019s disease in the adult. Nutritional management during initiation of treatment with miglustat [in French]. Presse Med. 2004;33:494\u20136.","journal-title":"Presse Med"},{"issue":"Suppl 3","key":"1060_CR43","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1007\/s10545-010-9193-4","volume":"33","author":"H Champion","year":"2010","unstructured":"Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, et al. Dietary modifications in patients receiving miglustat. J Inherit Metab Dis. 2010;33 Suppl 3:S379\u201383.","journal-title":"J Inherit Metab Dis"},{"key":"1060_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13023-015-0297-7","volume":"10","author":"T Remenova","year":"2015","unstructured":"Remenova T, Morand O, Amato D, Chadha-Boreham H, Tsurutani S, Marquardt T. A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat. Orphanet J Rare Dis. 2015;10:81.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-1060-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-016-1060-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-1060-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T17:57:20Z","timestamp":1657648640000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-016-1060-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1186\/s13256-016-1060-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]},"article-number":"315"}}